Medxtractor Doubles Down on B2B Licensing & mHealth


Ryan Allway

August 3rd, 2021

Psychedelics, Top Story


Medxtractor Corp. (CSE: MXT) (OTCQB: MXTTF) is known for its award-winning extraction equipment, but recently, the company refocused its efforts on its proprietary health-related databases, machine learning analysis, and plans to engage in B2B licensing and mHealth.

Mental health disorders are notoriously difficult to diagnose and treat. Unlike most other ailments, there isn’t a simple test that physicians can use to diagnose a patient with a disorder. Many mental health disorders have treatment options, but they aren’t nearly as safe and efficacious as conventional pharmaceuticals or therapies.

Medxtractor Corp. (CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. Using machine learning algorithms and qualified practitioner input, the company is leveraging that data to build tools that deliver digital diagnostic opinions.

The company’s initial focus is on predicting the potential benefits of psychedelic drugs on various mental health conditions and developing an mHealth consumer health application, called YMI, to predict an individual’s current and future mental and physical health conditions. The company anticipates launching both programs this year.

Data Bridge Market Research believes that psychedelics will grow at a 13.3% compound annual growth rate from $2.8 billion in 2020 to $7.6 billion by 2028. But, of course, the growth in the market will depend mainly on accurately diagnosing patients with certain mental illnesses and successfully treating those conditions with psychedelics.

Data Bridge sees strong psychedelics growth. Source: Data Bridge

“As the reference database was being developed, it became apparent that there were additional applications that could benefit from the same database,” said President James Durward. “While the original ‘business-to-business’ application anticipates licensing the database to researchers, practitioners, and developers in the psychedelics field, the YMI application targets the far broader consumer mHealth market.”

Click here to receive an investor presentation and corporate updates

GM Insights projects that the market for mHealth products will grow at a 30% compound annual growth rate from $56 billion in 2020 to more than $805 billion by 2030. While wearables have driven adoption thus far, applications that can translate the data generated from these wearables into actionable insights could see the most future growth.

GM Insights sees massive market growth. Source: GM Insights

Medxtractor’s health platform could be the key to unlocking both of these massive and growing markets. By combining mHealth data from wearables with its reference database, the company hopes to provide actionable health insights to consumers. Meanwhile, the same reference database could help psychedelics companies deliver on their promises.

In addition to targeting large markets with a compelling solution, the company is cultivating an attractive business model. The reference data it collects and its constantly improving machine learning algorithms create a moat that prevents competitors from quickly stepping into the market. At the same time, the software-based nature of the business could translate to higher profit margins and easy scalability into different verticals.

Click here to receive an investor presentation and corporate updates

Investors may want to look at the company as it gears up to launch its interactive website before August 31, 2021, and its business-to-business licensing before November 30, 2021. These catalysts could provide a key proof-of-concept and help the market better understand the story—ultimately setting it up for success.

Learn more by visiting the company’s website or downloading their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading